Bintrafusp alfa is in clinical development for the treatment of advanced, unresectable, or metastatic cervical cancer. Cervical cancer can be defined as advanced or metastatic when originates in the cervix and spreads to various other parts of the body. If cervical cancer is recurrent, metastatic or persistent, there are limited treatment options, with treatments usually aiming to alleviate symptoms and improve quality of life.
Bintrafusp alfa is a type of protein called an antibody, which can bind to a cancer-causing protein. Therefore, it activates the natural killer (NK) cell to attack the cancer cells. Bintrafusp alfa is administered by intravenous infusion (injection into the vein). If licensed, bintrafusp alfa would offer an additional treatment option for patients with advanced, unresectable and/or metastatic cervical cancer.
Afamitresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) in patients who have previously had chemotherapy. Both synovial sarcoma and MRCLS are two different types of soft tissue sarcomas (STS), a rare form of cancer that develops in the tissues that connect, support and surround other …